Molecular networking-based drug repurposing strategies for SARS-CoV-2 infection by targeting alpha-1-antitrypsin (SERPINA1)

Author:

Parameswaran Dakshinesh1,Gurumoorthy Premkumar Kuduva2,Munusamy Ravikumar2,Thangavelu Saravanan2,Selvaraj Jubie3,Akey Krishna Swaroop3,Chellappa Selvinthanuja1,Vivekanandan Lalitha1,Thangavelu Prabha1

Affiliation:

1. Nandha College of Pharmacy, Affiliated with The Tamil Nadu Dr. MGR Medical University-Chennai

2. Government Medical College and Hospital

3. JSS College of Pharmacy, JSS Academy of Higher Education & Research

Abstract

Abstract Background For a deeper comprehension of the condition and the development of more potent therapies, it is essential to understand COVID-19 pathogenesis. Transmembrane serine protease 2 (TMPRSS2) and disintegrin and metalloproteinase 17 (ADAM17) are two of the most significant proteases in the pathogenesis of COVID-19. An intrinsic tissue protector with antiviral and anti-inflammatory effects is called alpha-1-antitrypsin (A1AT), and it inhibits the protein TMPRSS2, which is crucial for SARS-CoV-2-S protein priming and viral infection. It also prevents the activity of pro-inflammatory chemicals like neutrophil elastase, TNF-, and IL-8.Objective According to current findings, repurposing available medications will result in more effective functioning than using newly designed medications. Based on this, we used FDA-approved drugs and did a computational study to find out what role A1AT plays in SARS-CoV-2 infections and how it stops Covid-19 from spreading.Method This computational study comprises the screening of FDA approved drugs by using molecular networking studies via cytoscape version 3.9.1 to identify any drugs binding interactions with SERPINA1, a gene that provides instructions for making a protein called A1AT, which is a type of serine protease inhibitor, followed by the generation of a pharmacophore model, virtual screening, and docking studies.Result The 22 compounds that were selected from this molecular-networking model were subjected to pharmacophore modelling followed by virtual screening. Through this screening, we have selected 22 molecules based on the Lipinski rule and low RMSD value, i.e., below 0.069235 Ao. From the ZINC database, the top six molecules discovered were found to have a higher affinity for A1AT when compared to the co-crystal ligand (-12.8236). The highest scores obtained by alpha-1-antitrypsin (PDB ID: 7NPK) are − 22.0254 and − 21.676 for ZINC00896543 and ZINC05316843, respectively.Conclusion Consequently, the molecules found by using different software programmes may be employed to control and treat COVID 19. By increasing the levels of A1AT, we may thus infer that these molecules have excellent action in the reversal of COVID-19.

Publisher

Research Square Platform LLC

Reference29 articles.

1. Origin and evolution of pathogenic coronaviruses;Cui J;Nat Rev Microbiol,2019

2. Coronavirus infection in equines: a review;Dhama K;Asian J Anim Vet Adv,2014

3. A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions;Jarada TN;J Cheminform,2020

4. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor;Hoffmann M;Cell,2020

5. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry;Simmons G;Proc Natl Acad Sci USA,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3